

Resource Summary Report

Generated by NIF on Jul 29, 2026

Purified anti-mouse CD19

RRID:AB_313637

Type: Antibody

Proper Citation

BioLegend Cat# 115502, RRID:AB_313637

Antibody Information

URL: http://antibodyregistry.org/AB_313637

Proper Citation: BioLegend Cat# 115502, RRID:AB_313637

Target Antigen: CD19

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, CyTOF??, IHC-F

Antibody Name: Purified anti-mouse CD19

Description: This monoclonal targets CD19

Target Organism: mouse

Clone ID: Clone 6D5

Antibody ID: AB_313637

Vendor: BioLegend

Catalog Number: 115502

Alternative Catalog Numbers: 115501

Record Creation Time: 20250820T015936+0000

Record Last Update: 20250820T122455+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-mouse CD19.

No alerts have been found for Purified anti-mouse CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chemla Y, et al. (2026) HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion. *Cell*, 189(1), 233.

Shi T, et al. (2025) CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases. *Cancer cell*.

Cheng JN, et al. (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. *Cancer cell*, 43(6), 1093.

Zhao Z, et al. (2025) Sick cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. *Immunity*, 58(6), 1484.

Canella A, et al. (2023) Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment. *Cell reports*, 42(8), 112891.

Li H, et al. (2022) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. *Cancer cell*, 40(1), 36.

Frede A, et al. (2022) B cell expansion hinders the stroma-epithelium regenerative cross talk during mucosal healing. *Immunity*, 55(12), 2336.

Hailemichael Y, et al. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. *Cancer cell*, 40(5), 509.

Goh W, et al. (2020) Hhex Directly Represses BIM-Dependent Apoptosis to Promote NK Cell Development and Maintenance. *Cell reports*, 33(3), 108285.

Gubin MM, et al. (2018) High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. *Cell*, 175(4), 1014.